Bictegravir/lenacapavir, sold under the brand name Bixlenvo, is a fixed-dose combination antiretroviral medication used for the treatment of HIV/AIDS. It contains bictegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor; and lenacapavir, an HIV-1 capsid inhibitor. It is taken by mouth. It was developed by Gilead Sciences.
Bictegravir/lenacapavir was approved for medical use in the United States in August 2026.
Medical uses Bictegravir/lenacapavir is indicated as a complete regimen for the treatment of HIV-1 in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to bictegravir or lenacapavir.
Society and culture Legal status Bictegravir/lenacapavir was approved for medical use in the United States in August 2026.
Names Bictegravir/lenacapavir is sold under the brand name Bixlenvo.
References
Further reading
External links